Trial Profile
Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Adverse reactions
- 26 Oct 2023 Planned End Date changed from 31 Jul 2023 to 31 Jul 2025.
- 26 Oct 2023 Planned primary completion date changed from 31 Jul 2023 to 31 Jul 2025.
- 02 Feb 2022 Status changed from recruiting to active, no longer recruiting.